Wayground logo

Free Printable Worksheets

Font size

S
M
L
XL
Worksheets

novoCare Quiz

Total questions: 16

Worksheet time: 8mins

Name
Class
Date
1.

Insulin detemir (IDet) differs from human insulin

a)

with the omission of aspartic acid at position 30 and attachment of myristic acid at position 29 by acylation.

b)

with the additon of threonine at position 30 and attachment of myristic acid at position 30 by acylation.

c)

with the omission of threonine at position 30 and attachment of myristic acid at position 29 by acylation.

d)

with the omission of proline at position 29 and attachment of myristic acid at position 29 by acylation.

2.

Insulin Detemir is produced by a process including recombinant DNA technology using

a)

Saccharomyces cerevisiae

b)

E. Coli

c)

Both A & B

3.

What are the main mechanisms underlying the prolonged action of insulin determir.

a)

Increased insulin self-association in the subcutaneous depot

b)

interstitial albumin binding

c)

plasma albumin binding

d)

All of above

4.

While insulin detemir is

a)

hexameric upon injection

b)

dimeric upon injection

c)

monomeric upon injection

none of above

d)

none of above

5.

Once in the bloodstream

a)

99% of these monomers bind to plasma albumin

b)

100% of these monomers bind to plasma albumin

c)

>98% of these monomers bind to plasma albumin

d)

97% of these monomers bind to plasma albumin

6.

In insulin aspart, substitution of amino acid ________ with ________ at position _____ is done.

a)

Arginine – Aspartic Acid – A28.

b)

Proline – Aspartic Acid – B28.

c)

Glycine – Myristic Acid – B23

d)

Lysine – Glutamic Acid – B30

7.

NovoMix® 30 should only be administered?

a)

Subcutaneously

b)

Intra muscular injection

c)

Intra venous injection

d)

Both a and b

8.

What is most common undesirable effect of NovoMix®?

a)

Neuropathy

b)

Retinopathy

c)

Hypoglycaemia

d)

Nephropathy

9.

What is the mechanism of action of NovoMix® 30?

a) Facilitated uptake of glucose following binding of insulin to receptors on muscle and fat cells.

b) Increase Incretin effect

c) Inhibition of hepatic glucose output

d) Both A & C

a)

Facilitated uptake of glucose following binding of insulin to receptors on muscle and fat cells.

b)

Increase Incretin effect

c)

Inhibition of hepatic glucose output

d)

Both A & C

10.

The onset of action of BiAsp 30 is:

a)

30-40 minutes

b)

30-40 minutes

c)

10-20 minutes

d)

5-8 minutes

11.

As compared to BHI 30, BiAsp 30 can be given:

a)

0-10 minutes before the meal

b)

30 minutes before the meal

c)

Immediately after or during the meal

d)

Both A & C

12.

Limitation of premixed insulins regimen include all EXCEPT

a)

Variability in glycaemic control

b)

Incomplete 24-hour basal coverage

c)

Need for re-suspension

d)

Complex titration schedule

13.

Co formulation of a basal insulin with a bolus in a single injection can

a)

Mimic physiological insulin secretion closely

b)

Avoid shoulder effect and variability of protaminated premix insulin

c)

Simplify the insulin regimen and lower the injection burden

d)

All the above

14.

Upon injection into the subcutaneous space the Insulin Aspart ___________ rapidly dissociate and enter the blood stream, while insulin degludec forms _____________ chains that slowly dissociate.

a)

Hexamers, multihexamer

b)

Monomers, multihexamer

c)

Monomers, dihexamers

d)

Hexamers, dihexamers

15.

Upon injection ___________ diffuses rapidly and change the conformation of dihexamers of insulin degludec to link together via side-chain contacts to assemble in long multihexamer chains.


a)

Chlorine

b)

Phenol

c)

Zinc

d)

Glutamic acid

16.

The mean half life of Insulin Degludec is longer than ___________ hours.

a)

12

b)

25

c)

42

d)

19